Less lubricants used with BAK-free medsOctober 1st 2014
Anti-glaucoma preparations that do not contain benzalkonium chloride (BAK) were associated with a change in lubricant use in a study of 240 glaucoma patients, suggesting reduction in some ocular surface disease symptoms, according to research published online.
To penetrate or not to penetrate in glaucoma surgery?September 1st 2014
In this article, comparative data is presented proving that trabeculectomy is more effective than non-penetrating options, however, does pose an increased risk of complications, leading to the conclusion that at the moment, procedures should be chosen on an individual basis.
European Commission approves combination eye dropsAugust 7th 2014
The European Commission has approved the eye drop suspension of brinzolamide 10 mg/mL and brimonidine tartrate 2 mg/mL to decrease elevated intraocular pressure (IOP) in adult patients who have open-angle glaucoma or ocular hypertension.
GATT novel 360? ab interno glaucoma procedureJuly 1st 2014
Gonioscopy-assisted transluminal trabeculotomy is a circumferential trabeculotomy performed via a minimally invasive, ab interno approach. Results from follow-up of 6 to 12 months in a series of 85 adult eyes with uncontrolled glaucoma show high IOP lowering, along with a reduced need for medication.
Positive CHMP opinion for glaucoma dropsJune 13th 2014
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for brinzolamide 10 mg/mL and brimonidine tartrate 2 mg/mL eye drops suspension (Simbrinza, Alcon) to decrease elevated intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension, for whom monotherapy provides insufficient IOP reduction.
Stents as effective as two medications in OAGJune 4th 2014
Implantation of two trabecular micro-bypass devices (iStent inject, Glaukos) reduced intraocular pressure (IOP) at least as effectively as a fixed combination of latanoprost/timolol in patients who had open-angle glaucoma that was not controlled by one medication, according to a recent study.
Dose-ranging study initiated for glaucoma candidateMay 23rd 2014
A Phase II dose-ranging study has been initiated for Amakem Therapeutics? glaucoma drug candidate AMA0076, a highly potent, locally acting Rho Kinase (ROCK) inhibitor designed to reduce intraocular pressure (IOP) while minimizing common ROCK inhibitor side effects such as hyperaemia.
Micro-stent is safe and effective after 2-yearsMay 21st 2014
A supracilliary micro-stent, when implanted in conjunction with cataract surgery, substantially reduces intraocular pressure (IOP) with minimal complications in patients with open-angle glaucoma, according to researchers in Germany and the US.
Valve and implant compared for refractory glaucomaMay 16th 2014
Patients with refractory glaucoma in whom a proprietary glaucoma implant was placed needed significantly less adjunctive medication to experience success in treatment compared with those who received a proprietary glaucoma valve. However, fewer of those in the latter group had serious postoperative complications, according to recently published 3-year outcomes.
Preservatives in glaucoma medicationsMay 1st 2014
Preservatives are an important component of topical multidose glaucoma medications. However, many glaucoma patients have symptoms of ocular surface disease (OSD), which can affect quality of life, treatment adherence and surgical outcomes. In this article, Prof. Baudouin offers straightforward steps to assess OSD and identify the patients most at risk.
Carbon dioxide laser assisted sclerectomy surgery (CLASS) is being used as an effective and safe, minimally invasive treatment for glaucoma. In this article, two surgeons at the forefront of research, development and implementation of this approach discuss this surgical option and its benefits for the ophthalmic market.
Training improves glaucoma-induced visual field defectsMarch 5th 2014
Repetitive activation of residual vision with training of the visual field borders and areas of residual vision can improve visual field defects caused by glaucoma and increase detection sensitivity, according to results from a randomized clinical trial.